S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ENTA Enanta Pharmaceuticals Inc

7.22

0.04 (0.56%)

Mar 07 2025 - Closed

Delayed by 15 minutes

Form ARS - Annual Report to Security Holders

Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Enanta Pharmaceuticals Charts.

Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Enanta Pharmaceuticals Charts.

Enanta Pharmaceuticals Inc News

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Friday 14 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 12 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 12 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 10 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
Monday 10 February 2025 (4 weeks ago) • Business Wire

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Monday 27 January 2025 (1 month ago) • Edgar (US Regulatory)

More Enanta Pharmaceuticals Inc News Articles

Asia Broadband (PK)

Kraig Biocraft Laborator... (QB)

Lightwave Logic

Good Vibrations Shoes (PK)

Voip Pal Com (QB)

Elite Pharmaceuticals (QB)

Digital Brand Media and ... (PK)

Northwest Biotherapeutics (QB)

Anavex Life Sciences

Fannie Mae (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions